ArticleClinical and translational gastroenterology2026
Efficacy and Safety of Long-Term Treatment With Budesonide Orodispersible Tablets in Patients With Eosinophilic Esophagitis.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionBudesonide orodispersible tablets (BOT) has improved eosinophilic esophagitis (EoE) outcomes. This study aimed to evaluate in real-life the efficacy of BOT and adverse events in induction and maintenance therapy.
methodsPatients with EoE receiving BOT (2 mg/day induction, 1 mg/day maintenance) were retrospectively analyzed over a 1-year follow-up. Clinical (Straumann Dysphagia Index [SDI]), endoscopic (Endoscopic Reference Score [EREFS]), and histological (eosinophils <15/HPF) responses were assessed at 12 weeks (T1) and 52 weeks (T2).
resultsAmong 104 patients enrolled, at T1 97.8% of patients achieved histologic remission and 70.3% maintained remission at T2 with a significant improvement of EREFS and SDI. Higher SDI during induction (odds ratio [OR]: 0.72; 95% CI: 0.56-0.93) and maintenance (OR: 0.65; 95% CI: 0.52-0.82) predicted loss of histologic remission at T2. BOT-proton pump inhibitor (PPI) coadministration during maintenance therapy increased the probability for histological response at T2 (OR: 7.8; 95% CI: 2.4-25.4). After induction, significant increase in incidence of erosive esophagitis was observed (2.2% vs 13.0%, P = 0.013), with BOT-PPI coadministration being protective toward it (OR: 0.14; 95% CI: 0.03-0.54). Local candidiasis was the most common adverse events at T1 and T2. Risk factors of candidiasis included a history of gastroesophageal reflux disease (OR: 3.71; 95% CI: 1.14-12.09), EoE family history (OR: 16.94; 95% CI: 1.78-161.4), oral allergy syndrome (OR: 3.53; 95% CI: 1.29-9.66). DISCUSSION: BOT is effective and overall safe in inducing and maintaining EoE remission. Erosive esophagitis incidence is higher during BOT therapy, supporting BOT-PPI combination in select cases. Clinical monitoring with SDI may help guide maintenance therapy and follow-up timing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.